The reported increase in revenue and shipment of new instruments suggests positive market reception and growth potential for Singular Genomics. The preliminary nature of the report means full details are pending, but the initial figures are promising and likely to be viewed positively by investors. The launch of new consumable kits also indicates ongoing product development and potential for future revenue streams.